CN116421531B - 一种保湿抗敏护肤霜及其制备方法 - Google Patents
一种保湿抗敏护肤霜及其制备方法 Download PDFInfo
- Publication number
- CN116421531B CN116421531B CN202310141662.XA CN202310141662A CN116421531B CN 116421531 B CN116421531 B CN 116421531B CN 202310141662 A CN202310141662 A CN 202310141662A CN 116421531 B CN116421531 B CN 116421531B
- Authority
- CN
- China
- Prior art keywords
- skin
- parts
- borneol
- moisturizing
- mixing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002884 skin cream Substances 0.000 title claims abstract description 65
- 230000003020 moisturizing effect Effects 0.000 title claims abstract description 46
- 230000003266 anti-allergic effect Effects 0.000 title claims abstract description 38
- 238000002360 preparation method Methods 0.000 title claims abstract description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 36
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 29
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims abstract description 25
- 229940116229 borneol Drugs 0.000 claims abstract description 25
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims abstract description 25
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims abstract description 25
- 239000007788 liquid Substances 0.000 claims abstract description 25
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 22
- 238000003756 stirring Methods 0.000 claims abstract description 22
- 238000002156 mixing Methods 0.000 claims abstract description 21
- 239000003921 oil Substances 0.000 claims abstract description 14
- 235000019198 oils Nutrition 0.000 claims abstract description 14
- 150000001413 amino acids Chemical class 0.000 claims abstract description 11
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 11
- 239000003906 humectant Substances 0.000 claims abstract description 11
- 235000019482 Palm oil Nutrition 0.000 claims abstract description 10
- 235000021355 Stearic acid Nutrition 0.000 claims abstract description 10
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims abstract description 10
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000002540 palm oil Substances 0.000 claims abstract description 10
- 239000008117 stearic acid Substances 0.000 claims abstract description 10
- 239000004006 olive oil Substances 0.000 claims abstract description 9
- 235000008390 olive oil Nutrition 0.000 claims abstract description 9
- 239000002253 acid Substances 0.000 claims abstract description 8
- 238000010438 heat treatment Methods 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims description 39
- 150000001637 borneol derivatives Chemical class 0.000 claims description 26
- 239000000463 material Substances 0.000 claims description 18
- CJJMAWPEZKYJAP-UHFFFAOYSA-N 3-hydroxyadamantane-1-carboxylic acid Chemical compound C1C(C2)CC3CC2(O)CC1(C(=O)O)C3 CJJMAWPEZKYJAP-UHFFFAOYSA-N 0.000 claims description 14
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 8
- 238000006243 chemical reaction Methods 0.000 claims description 8
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 claims description 6
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 claims description 6
- 241000205585 Aquilegia canadensis Species 0.000 claims description 6
- 244000207740 Lemna minor Species 0.000 claims description 6
- 235000006439 Lemna minor Nutrition 0.000 claims description 6
- 235000001855 Portulaca oleracea Nutrition 0.000 claims description 6
- -1 borneol ester Chemical class 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 4
- 238000005886 esterification reaction Methods 0.000 claims description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 4
- 230000001139 anti-pruritic effect Effects 0.000 claims description 3
- 239000003908 antipruritic agent Substances 0.000 claims description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 2
- 241000050051 Chelone glabra Species 0.000 claims description 2
- 244000246386 Mentha pulegium Species 0.000 claims description 2
- 235000016257 Mentha pulegium Nutrition 0.000 claims description 2
- 235000004357 Mentha x piperita Nutrition 0.000 claims description 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 230000032050 esterification Effects 0.000 claims description 2
- 235000019253 formic acid Nutrition 0.000 claims description 2
- 235000001050 hortel pimenta Nutrition 0.000 claims description 2
- 229940107666 astragalus root Drugs 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 18
- 201000004624 Dermatitis Diseases 0.000 abstract description 7
- 208000003251 Pruritus Diseases 0.000 abstract description 6
- 206010061218 Inflammation Diseases 0.000 abstract description 5
- 230000007803 itching Effects 0.000 abstract description 5
- 230000008439 repair process Effects 0.000 abstract description 5
- 230000004089 microcirculation Effects 0.000 abstract description 4
- AVBJHQDHVYGQLS-AWEZNQCLSA-N (2s)-2-(dodecanoylamino)pentanedioic acid Chemical class CCCCCCCCCCCC(=O)N[C@H](C(O)=O)CCC(O)=O AVBJHQDHVYGQLS-AWEZNQCLSA-N 0.000 description 27
- 238000012360 testing method Methods 0.000 description 27
- 239000012071 phase Substances 0.000 description 11
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 10
- 239000000047 product Substances 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 8
- 239000006071 cream Substances 0.000 description 8
- 235000011187 glycerol Nutrition 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 206010070834 Sensitisation Diseases 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- UFLHIIWVXFIJGU-ARJAWSKDSA-N (Z)-hex-3-en-1-ol Chemical compound CC\C=C/CCO UFLHIIWVXFIJGU-ARJAWSKDSA-N 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 241000756943 Codonopsis Species 0.000 description 4
- 239000009636 Huang Qi Substances 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 235000006679 Mentha X verticillata Nutrition 0.000 description 4
- 235000002899 Mentha suaveolens Nutrition 0.000 description 4
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 208000026935 allergic disease Diseases 0.000 description 4
- 230000007815 allergy Effects 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- 238000007405 data analysis Methods 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010040880 Skin irritation Diseases 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 239000012488 sample solution Substances 0.000 description 3
- 230000037307 sensitive skin Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 230000036556 skin irritation Effects 0.000 description 3
- 231100000475 skin irritation Toxicity 0.000 description 3
- 208000036649 Dysbacteriosis Diseases 0.000 description 2
- 208000027244 Dysbiosis Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 239000002390 adhesive tape Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 230000007140 dysbiosis Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 210000000245 forearm Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 230000037384 skin absorption Effects 0.000 description 2
- 231100000274 skin absorption Toxicity 0.000 description 2
- 230000005808 skin problem Effects 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- KZRXPHCVIMWWDS-AWEZNQCLSA-N (4S)-4-amino-5-dodecanoyloxy-5-oxopentanoic acid Chemical class CCCCCCCCCCCC(=O)OC(=O)[C@@H](N)CCC(O)=O KZRXPHCVIMWWDS-AWEZNQCLSA-N 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000001804 debridement Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002951 depilatory effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000000118 hair dye Substances 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/634—Forsythia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Dermatology (AREA)
- Birds (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明公开了一种保湿抗敏护肤霜及其制备方法,涉及医药护肤品技术领域。该保湿抗敏护肤霜的制备方法,包括:S1:取单脂酸、硬脂酸和甘油混合,加入橄榄油、棕榈油和乳化剂,加热混合搅拌获得油相;S2:取煎煮好的中药水,加入氨基酸保湿剂,加热混合搅拌得到水相;S3:取加热好的油相加入水相中混合搅拌,然后加入冰片继续搅拌得到保湿抗敏护肤霜。本发明提供的护肤霜能够有效缓解肌肤搔痒情况,改善皮肤微循环微炎症,增加皮肤天然保护修复能力,进而明显降低肌肤的过敏率;且具有更优的保湿锁水功效。
Description
技术领域
本发明属于医药护肤品技术领域,具体涉及一种保湿抗敏护肤霜及其制备方法。
背景技术
随着社会的发展、人们的生活水平不断提高,环境污染也随之加重,来自工作、生活等各方面的社会压力也越来越大,再加上一些高碱性或/和强氧化的外用制剂在临床应用上也越来越多,例如双氧水消毒清创剂、脱毛剂、染发剂等,伴随而来的各类皮肤问题困扰着人们,特别是过敏、瘙痒等皮肤问题,更是让人们苦不堪言。人们对安全有效的天然抗过敏、止痒产品的需求越来越大。
市面上已有的乳霜以封闭剂为主,隔离皮肤与外界环境,减轻环境中各种微粒和刺激因子对皮肤的伤害。但存在的问题是,对于敏感肌肤的皮肤缺水状态和微炎症缺乏作用,这导致这些乳膏的使用,无法真正改善皮肤的状态,只能持续使用部分缓解。且普通的乳膏只能起封闭作用,而很难真正被皮肤吸收,敏感肌肤的屏障缺陷、水分脱失、菌丛失调等问题都无法解决。
发明内容
本发明的目的在于提供一种保湿抗敏护肤霜及其制备方法,该护肤霜能够有效缓解肌肤搔痒情况,改善皮肤微循环微炎症,增加皮肤天然保护修复能力,进而明显降低肌肤的过敏率;且具有更优的保湿锁水功效。
本发明为实现上述目的所采取的技术方案为:
一种保湿抗敏护肤霜的制备方法,包括:
S1:取单脂酸、硬脂酸和甘油混合,加入橄榄油、棕榈油和乳化剂,加热混合搅拌获得油相;
S2:取煎煮好的中药水,加入氨基酸保湿剂,加热混合搅拌得到水相;
S3:取加热好的油相加入水相中混合搅拌,然后加入冰片继续搅拌得到保湿抗敏护肤霜。
进一步的,步骤S1和S2中的加热温度为80~85℃。
进一步的,中药水由混合药材通过煎煮获得。
进一步的,混合药材包括薄荷、金银花、连翘、浮萍、党参、黄芩、黄芪。本发明采用多种中药材提取物复混,与其它组分复配使用制得具有保湿抗敏功效的护肤霜,与普通的化学霜剂相比,添加了中药植物成分的保湿霜,对于敏感肌肤的水分锁定、菌丛失调平衡、微循环微炎症的改善都有了显著的作用。且本发明提供的中药植物成分的保湿防敏霜对皮肤的损害少,能够有效的改善皮肤的干燥和微炎症,预防皮肤的过敏,可广泛应用于防治皮肤过敏、炎症损伤的护肤品或药品中。
进一步的,混合药材包括:按重量份计,10~20份薄荷、5~15份金银花、8~16份连翘、5~10份浮萍、10~15份党参、9~15份黄芩、10~16份黄芪。
本发明还公开了中药水的制备方法,包括:
按照重量份配比取各中药材,加水浸泡30~60min,加水量高出药材1~2cm;然后滤去水分,加入高出药草2~3cm的水进行第一次煎煮,煮沸20~30min,过滤得到第一次煎煮液;接着再加入水进行第二次煎煮,加水量为第一次煎煮加水量的1/3~1/2,煮沸时间15~20min,得到第二次煎煮水;将两次煎煮水合并,蒸发浓缩至1/2~2/3体积量获得中药水。
进一步具体的,上述保湿抗敏护肤霜的制备方法,包括:
S1:取单脂酸、硬脂酸和甘油混合,加入橄榄油、棕榈油和乳化剂,80~85℃水浴条件下混合搅拌10~20min获得油相,保温备用;
S2:取煎煮好的中药水,80~85℃水浴条件下加入氨基酸保湿剂混合搅拌5~15min得到水相,保温备用;
S3:取加热好的油相加入水相中,保温均质3~5min,保温搅拌20~30min,降温至50℃,加入冰片保温搅拌1~2h,然后继续降温至室温得到保湿抗敏护肤霜。
本发明又公开了一种保湿抗敏护肤霜,包括:按重量份计,500~600份中药水,18~24份单脂酸,90~120份硬脂酸,20~30份甘油,140~160份橄榄油,35~45份棕榈油,40~50份乳化剂,90~110份氨基酸保湿剂,5~12份冰片。
优选地,冰片由冰片衍生物替代;所述冰片衍生物包括冰片酯类衍生物。
进一步的,冰片酯类衍生物包括3-羟基-1-金刚烷甲酸酯化改性冰片获得的冰片衍生物。本发明采用3-羟基-1-金刚烷甲酸酯化改性冰片制备获得冰片衍生物,表现出更加优异的生物活性。与其它组分复配制备得到护肤霜,具有更强的促皮肤渗透作用,可有效提高皮肤对护肤霜中药成分的渗透浓度和速度,更有利于皮肤吸收,快速发挥抗敏、保湿等作用。
需要说明的是,上述冰片衍生物的制备方法,包括:
取3-羟基-1-金刚烷甲酸溶于氯仿中,加入EDCI和NHS,再加入冰片,室温下搅拌过夜,采用TCL监测反应程度,反应完全后,加入等体积纯化水洗涤3~5次,取油层加入过量无水硫酸钠干燥、过滤,然后旋蒸除溶剂,采用柱层析纯化得到冰片衍生物。
进一步的,3-羟基-1-金刚烷甲酸与氯仿的固液比为0.05~0.1g:1mL;3-羟基-1-金刚烷甲酸、EDCI和NHS的摩尔比为1:1.8~2:1.8~2;冰片与3-羟基-1-金刚烷甲酸的摩尔比为1:0.9~1。
本发明的又一目的在于,公开了上述冰片衍生物在制备抗过敏、止痒或/和抗炎的外用护肤品或药品中的用途。
相比于现有技术,本发明具有如下有益效果:
本发明公开了含有中药提取物成分的保湿抗敏护肤霜,多种成分协同增效,能够有效缓解肌肤搔痒、灼痛以及炎性过敏等症状,明显增加了皮肤天然保护修复的能力,进而能够有效降低肌肤的过敏率。且本发明采用3-羟基-1-金刚烷甲酸酯化改性冰片制备获得冰片衍生物,与其它组分复配使用,表现出具有更强的促皮肤渗透作用,可有效提高皮肤对护肤霜中药成分的渗透浓度和速度,更有利于皮肤吸收,快速发挥抗敏、保湿等作用。
因此,本发明提供了一种保湿抗敏护肤霜及其制备方法,该护肤霜能够有效缓解肌肤搔痒情况,改善皮肤微循环微炎症,增加皮肤天然保护修复能力,进而明显降低肌肤的过敏率;且具有更优的保湿锁水功效。
附图说明
图1是本发明中实施例6制备的月桂酰谷氨酸衍生物以及月桂酰谷氨酸的红外光谱。
具体实施方式
为使本发明实施例的目的、技术方案和优点更加清楚,下面将结合实施例对本发明的各实施方式进行详细的阐述。然而,本领域的普通技术人员可以理解,在本发明各实施方式中,为了使读者更好地理解本申请而提出了许多技术细节。但是,即使没有这些技术细节和基于以下各实施方式的种种变化和修改,也可以实现本申请所要求保护的技术方案。
本发明实施例用乳化剂为SM-617,市购;氨基酸保湿剂购自宣城晶瑞新材料有限公司。
实施例1:
一种保湿抗敏护肤霜,包括:按重量份计,580份中药水,22份单脂酸,112份硬脂酸,26份甘油,152份橄榄油,42份棕榈油,46份乳化剂,104份氨基酸保湿剂,10份冰片。
一种保湿抗敏护肤霜的制备:
S1:取单脂酸、硬脂酸和甘油混合,加入橄榄油、棕榈油和乳化剂,80℃水浴条件下混合搅拌15min获得油相,保温备用;
S2:取煎煮好的中药水,80℃水浴条件下加入氨基酸保湿剂混合搅拌12min得到水相,保温备用;
S3:取加热好的油相加入水相中,保温均质5min,保温搅拌25min,降温至50℃,加入冰片保温搅拌2h,然后继续降温至室温得到保湿抗敏护肤霜。
中药水的制备:
按照重量份配比取各中药材,加水浸泡50min,加水量高出药材2cm;然后滤去水分,加入高出药草3cm的水进行第一次煎煮,煮沸30min,过滤得到第一次煎煮液;接着再加入水进行第二次煎煮,加水量为第一次煎煮加水量的1/2,煮沸时间20min,得到第二次煎煮水;将两次煎煮水合并,蒸发浓缩至1/2体积量获得中药水。
进一步的,中药材包括:按重量份计,15份薄荷、12份金银花、12份连翘、8份浮萍、13份党参、13份黄芩、12份黄芪。
实施例2:
一种保湿抗敏护肤霜与实施例1的不同之处在于,其原料组分如下:
按重量份计,520份中药水,20份单脂酸,100份硬脂酸,22份甘油,146份橄榄油,38份棕榈油,42份乳化剂,96份氨基酸保湿剂,8份冰片。
保湿抗敏护肤霜的制备方法与实施例1相同。
中药水的制备方法与实施例1相同,不同之处在于其混合药材组分,具体为:
按重量份计,11份薄荷、6份金银花、9份连翘、7份浮萍、10份党参、11份黄芩、10份黄芪。
实施例3:
一种保湿抗敏护肤霜与实施例1的不同之处在于,其原料组分如下:
按重量份计,546份中药水,24份单脂酸,90份硬脂酸,20份甘油,160份橄榄油,35份棕榈油,40份乳化剂, 110份氨基酸保湿剂,5份冰片。
保湿抗敏护肤霜的制备方法与实施例1相同。
中药水的制备方法与实施例1相同,不同之处在于其混合药材组分,具体为:
按重量份计,10份薄荷、15份金银花、8份连翘、9份浮萍、15份党参、9份黄芩、14份黄芪。
实施例4:
一种保湿抗敏护肤霜与实施例1的不同之处在于,采用本实施例制备的冰片衍生物替代冰片。
冰片衍生物的制备:
取3-羟基-1-金刚烷甲酸溶于氯仿(固液比为0.08g:1mL)中,加入EDCI和NHS(3-羟基-1-金刚烷甲酸、EDCI和NHS的摩尔比为1:2:1.8),再加入冰片(与3-羟基-1-金刚烷甲酸的摩尔比为1:0.95),室温下搅拌过夜,采用TCL监测反应程度,反应完全后,加入等体积纯化水洗涤3次,取油层加入过量无水硫酸钠干燥、过滤,然后旋蒸除溶剂,采用柱层析纯化得到冰片衍生物;1H NMR(400 MHz,CDCl3):δ:4.37(m,1H,O-CH),1.0~2.0(m,21H,-CH、-CH 2),0.90、0.81(s,9H,-CH 3)。
保湿抗敏护肤霜的制备方法与实施例1相同。
中药水的制备方法以及混合药材组分与实施例1相同。
实施例5:
一种保湿抗敏护肤霜与实施例2的不同之处在于,采用本实施例制备的冰片衍生物替代冰片。
冰片衍生物的制备与实施例4相同
保湿抗敏护肤霜的制备方法与实施例2相同。
中药水的制备方法以及混合药材组分与实施例2相同。
实施例6:
一种保湿抗敏护肤霜与实施例1的不同之处在于,其原料组分中还加入月桂酰谷氨酸衍生物。
需要说明的是,月桂酰谷氨酸衍生物由月桂酰谷氨酸和叶醇通过酯化反应制备获得。本发明采用叶醇对月桂酰谷氨酸进行化学修饰,通过酯化反应制备获得月桂酰谷氨酸衍生物,具有更优的表面活性性能,与其它组分复配使用,能够进一步增强护肤霜产品的保湿性能,且进一步改善了护肤霜的抗敏修复能力。
进一步的,上述月桂酰谷氨酸衍生物的制备方法,包括:
取月桂酰谷氨酸,加入对甲苯磺酸一水合物以及叶醇,-0.05~-0.08MPa、110~130℃油浴条件下反应3~5h,冷却后使用甲醇进行多次洗涤,常温静置1~3h,取上层油状液体,真空干燥得到月桂酰谷氨酸衍生物。
进一步的,对甲苯磺酸一水合物与月桂酰谷氨酸的摩尔比为1:15~17;叶醇与月桂酰谷氨酸的摩尔比为2~3:1。
于本实施例中,月桂酰谷氨酸衍生物的制备为:
取月桂酰谷氨酸,加入对甲苯磺酸一水合物(与月桂酰谷氨酸的摩尔比为1:16)以及叶醇(与月桂酰谷氨酸的摩尔比为2.4:1),-0.08MPa、120℃油浴条件下反应4h,冷却后使用甲醇进行多次洗涤,常温静置2h,取上层油状液体,真空干燥得到月桂酰谷氨酸衍生物。
保湿抗敏护肤霜的制备方法与实施例1的不同之处在于,在步骤S3中加入月桂酰谷氨酸衍生物。
中药水的制备方法以及混合药材组分与实施例1相同。
实施例7:
一种保湿抗敏护肤霜与实施例4的不同之处在于,其原料组分中还加入月桂酰谷氨酸衍生物。
月桂酰谷氨酸衍生物的制备与实施例6相同。
保湿抗敏护肤霜的制备方法与实施例4的不同之处在于,在步骤S3中加入月桂酰谷氨酸衍生物。
中药水的制备方法以及混合药材组分与实施例4相同。
试验例1:
红外表征
测试采用傅里叶变换红外光谱仪进行,测试波长4000~500cm-1。
对实施例6中制备的月桂酰谷氨酸衍生物及其月桂酰谷氨酸进行上述测试,结果如图1所示。从图中分析可知,相比于月桂酰谷氨酸的红外测试结果,在实施例6制备的月桂酰谷氨酸衍生物的红外光谱中,在1740cm-1附近出现酯基中C=O的特征吸收峰,1610cm-1附近出现双键的特征吸收峰,以上结果表明实施例5中月桂酰谷氨酸衍生物成功制备。
试验例2:
保湿性能测定
试验对象:年龄在20~50周岁之间符合要求的志愿者40名,随机分为8组(实验组包括实施例1-7制备的护肤霜以及市售竞品),用电容法皮肤水分测定仪预检,前臂测试区域的基础值在15-45(C.U.)之间。
具体测试过程:受试者在20℃、40~60%湿度的环境中,先用干净纸巾擦拭手臂内侧标记好的受试部位,静坐30min后测定空白值;然后均匀涂抹样品,涂抹量为2mg/cm2,涂抹30min后测定一次水分值;等待6h后进行皮肤水分值测试,计算前后水分变化率(下降率)。
对实施例1~7制备的护肤霜进行上述测试,结果如表1所示:
表1 人体保湿测试水分值结果
从表1中的数据分析可知,使用了实施例1制备的护肤霜后,水分下降率明显低于市售竞品的,表明本发明实施例1制备的护肤霜具有更优的保湿性能,保湿效果更佳。实施例4的效果要好于实施例1,实施例5的效果好于实施例2,表明采用3-羟基-1-金刚烷甲酸修饰冰片制备冰片衍生物,与其它组分复配制得护肤霜,能够有效增强护肤霜对皮肤的保湿效果。此外,实施例6的效果要好于实施例1的,实施例7的效果好于实施例4的,表明采用叶醇改性月桂酰谷氨酸制备获得月桂酰谷氨酸衍生物,作为功能成分加入护肤霜中,能够进一步增强护肤霜对皮肤的保湿性能。
试验例3:
抗敏性能测试
采用实施例1-7制备的护肤霜以及市售竞品进行临床观察,每组10例,观察前皮肤主要表现为肌肤敏感、瘙痒不适且有的常年发作。使用方法是:每日洁面后,在肌肤上和易发部位涂抹待测样品适量,早晚各一次。观察1个月后皮肤情况。
结果判断标准为:无效,临床症状、皮肤敏感未见转好;有效,临床症状减轻,皮肤敏感反应部分消退或消失,减小或减少;治愈,临床症状消失、一个月内再无皮肤敏感反应。
结果分析:
测试结果如表2所示:
表2 抗敏性能测试结果
从表2中的数据分析可知,使用了实施例1制备的护肤霜的治疗效果明显好于市售竞品的,表明本发明实施例1制备的护肤霜具有更优的抗敏修复性能。实施例4的效果要好于实施例1,实施例5的效果好于实施例2,表明采用3-羟基-1-金刚烷甲酸修饰冰片制备冰片衍生物,与其它组分复配制得护肤霜,起到协同增强作用,能够有效提升护肤霜对皮肤的抗敏修复能力。此外,实施例6的效果要好于实施例1的,实施例7的效果好于实施例4的,表明采用叶醇改性月桂酰谷氨酸制备获得月桂酰谷氨酸衍生物,作为功能成分加入护肤霜中,能够进一步增强护肤霜对皮肤的保抗敏修复效果。
试验例4:
皮肤刺激性测定
具体测试方法为:选择28名志愿者,25-45周岁之间,男女各半,随机分为7组,用注射器取样品溶液(1g待测样品溶于100mL PBS溶液中)0.05mL置于斑试胶带的药室内,然后立即将含有药品的斑试胶带纵向贴于受试者左前臂的正常健康皮肤上,并轻压药室除去空气,使得样品分布均匀。每隔24h贴肤一次,揭开贴片后30min,按照CTFA指南的术语进行检查,共进行5次贴斑试验。皮肤刺激性试验的鉴定标准如表3所示:
表3 鉴定标准
对实施例1~7制备的护肤霜进行上述测试,结果如表4所示:
表4 皮肤刺激性测试结果
从表4中的数据分析可知,本发明制备的保湿抗敏护肤霜对皮肤无刺激,且无阳性反应,表明本发明公开的护肤霜产品安全性高,温和性好。
试验例5:
皮肤渗透促进效果测定
测试方法具体为:以中药水中含有的总多糖作为检验指标,采用Franz扩散池对皮肤渗透促进效果进行评价。取-80℃冻存的皮肤膜置于60℃下解冻复苏,置于Franz扩散池中,接受液为生理盐水。池内置磁力搅拌子,转速350r/min,恒温水浴37℃,先将接收池和供给池各加入7mL生理盐水平衡30min,然后将接收池内的液体更换为新鲜的生理盐水,供给室开放式给药,定量移取7mL待测样品溶液(2g待测样品溶液10mL 40%乙醇水溶液中),于1、2、3、4、5、6、8、10、12、24、36、48h后,取1mL接收液并及时补充等量新鲜接收液。采用紫外分光光度法测定相应波长处的吸光度,依据标准曲线求出相应药物浓度,并计算单位面积稳态透皮速率(μg·cm-2·h-1)。
对实施例1-2、实施例4-5制备的护肤霜进行上述测试,结果如表5所示:
表5 透皮吸收测试结果
样品 | 稳态透皮速率(μg·cm-2·h-1) |
实施例1 | 1.41 |
实施例2 | 1.37 |
实施例4 | 2.03 |
实施例5 | 1.98 |
从表5中的数据分析可知,实施例4制备的护肤霜的稳态透皮速率明显高于实施例1的,实施例5的效果好于实施例2,表明采用3-羟基-1-金刚烷甲酸修饰冰片制备冰片衍生物,与其它组分复配制得护肤霜,能够有效增强护肤霜的透皮渗透吸收效果,进而促进护肤霜成分作用的发挥,增强其功能性。
上述实施例中的常规技术为本领域技术人员所知晓的现有技术,故在此不再详细赘述。
以上所述,仅为本发明的具体实施方式,但本发明的保护范围并不局限于此,任何熟悉本技术领域的技术人员在本发明揭露的技术范围内,可轻易想到变化或替换,都应涵盖在本发明的保护范围之内。因此,本发明的保护范围应以所述权利要求的保护范围为准。
Claims (3)
1.一种保湿抗敏护肤霜的制备方法,包括:
S1:取单脂酸、硬脂酸和甘油混合,加入橄榄油、棕榈油和乳化剂,加热混合搅拌获得油相;
S2:取煎煮好的中药水,加入氨基酸保湿剂,加热混合搅拌得到水相;
S3:取加热好的油相加入水相中混合搅拌,然后加入冰片衍生物继续搅拌得到保湿抗敏护肤霜;
按重量份计,500~600份中药水,18~24份单脂酸,90~120份硬脂酸,20~30份甘油,140~160份橄榄油,35~45份棕榈油,40~50份乳化剂,90~110份氨基酸保湿剂,5~12份冰片衍生物;
所述冰片衍生物制备中,将3-羟基-1-金刚烷甲酸、EDCI、NHS和冰片混合于氯仿中,室温反应后经分离纯化得到冰片衍生物,3-羟基-1-金刚烷甲酸、EDCI和NHS的摩尔比为1:1.8~2:1.8~2;冰片与3-羟基-1-金刚烷甲酸的摩尔比为1:0.9~1;
所述中药水由混合药材通过煎煮获得,所述混合药材包括薄荷、金银花、连翘、浮萍、党参、黄芩、黄芪。
2.根据权利要求1所述的保湿抗敏护肤霜的制备方法,其特征在于:所述步骤S1和S2中的加热温度为80~85℃。
3.冰片衍生物在制备抗过敏、止痒或/和抗炎的外用护肤品或药品中的用途,所述冰片衍生物包括冰片酯类衍生物,冰片酯类衍生物包括3-羟基-1-金刚烷甲酸酯化改性冰片获得的冰片衍生物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310141662.XA CN116421531B (zh) | 2023-02-21 | 2023-02-21 | 一种保湿抗敏护肤霜及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310141662.XA CN116421531B (zh) | 2023-02-21 | 2023-02-21 | 一种保湿抗敏护肤霜及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116421531A CN116421531A (zh) | 2023-07-14 |
CN116421531B true CN116421531B (zh) | 2024-04-09 |
Family
ID=87091463
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310141662.XA Active CN116421531B (zh) | 2023-02-21 | 2023-02-21 | 一种保湿抗敏护肤霜及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116421531B (zh) |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20080099570A (ko) * | 2007-05-10 | 2008-11-13 | 조선대학교산학협력단 | 복합 생약 추출물을 유효성분으로 함유하는 피부염 질환의예방 및 치료용 조성물 |
CN103989601A (zh) * | 2014-05-29 | 2014-08-20 | 皖南医学院 | 一种焕颜保湿嫩肤面霜及其制备方法 |
KR101769419B1 (ko) * | 2016-02-25 | 2017-08-18 | 원광보건대학교 산학협력단 | 다중기능성 영양크림의 혼합 조성물 및 제조방법 |
CN107519035A (zh) * | 2017-08-30 | 2017-12-29 | 李伟 | 一种明胶‑水解明胶复配物在护肤产品中的应用 |
CN108619076A (zh) * | 2018-06-21 | 2018-10-09 | 佛山汇沐化学科技有限公司 | 一种适用于敏感肌肤的美白保湿乳液 |
CN112716842A (zh) * | 2021-01-07 | 2021-04-30 | 潘伟 | 一种具有长效保湿效果的有机保湿霜及其制备方法 |
CN112891239A (zh) * | 2021-03-19 | 2021-06-04 | 唐发彬 | 一种含胶原三肽的美白抗衰老护肤霜 |
CN113144116A (zh) * | 2021-06-10 | 2021-07-23 | 李茂慧 | 一种用于祛痘的制剂及其制备方法 |
-
2023
- 2023-02-21 CN CN202310141662.XA patent/CN116421531B/zh active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20080099570A (ko) * | 2007-05-10 | 2008-11-13 | 조선대학교산학협력단 | 복합 생약 추출물을 유효성분으로 함유하는 피부염 질환의예방 및 치료용 조성물 |
CN103989601A (zh) * | 2014-05-29 | 2014-08-20 | 皖南医学院 | 一种焕颜保湿嫩肤面霜及其制备方法 |
KR101769419B1 (ko) * | 2016-02-25 | 2017-08-18 | 원광보건대학교 산학협력단 | 다중기능성 영양크림의 혼합 조성물 및 제조방법 |
CN107519035A (zh) * | 2017-08-30 | 2017-12-29 | 李伟 | 一种明胶‑水解明胶复配物在护肤产品中的应用 |
CN108619076A (zh) * | 2018-06-21 | 2018-10-09 | 佛山汇沐化学科技有限公司 | 一种适用于敏感肌肤的美白保湿乳液 |
CN112716842A (zh) * | 2021-01-07 | 2021-04-30 | 潘伟 | 一种具有长效保湿效果的有机保湿霜及其制备方法 |
CN112891239A (zh) * | 2021-03-19 | 2021-06-04 | 唐发彬 | 一种含胶原三肽的美白抗衰老护肤霜 |
CN113144116A (zh) * | 2021-06-10 | 2021-07-23 | 李茂慧 | 一种用于祛痘的制剂及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN116421531A (zh) | 2023-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103784368B (zh) | 具有舒缓美白功效的护肤组合物、膏霜及其制备方法 | |
CN102068610B (zh) | 具有保湿滋润功效的中药组合物、制剂及其制备方法 | |
CN103127269A (zh) | 一首中药复方的提取物及含有所述活性成分的化妆品 | |
CN105726391B (zh) | 一种铁皮石斛沐浴露 | |
CN111529413A (zh) | 一种烟酰胺胶囊面膜及其制备和使用方法 | |
CN111388376A (zh) | 一种茉莉草本抗敏舒缓面膜及其制备方法 | |
CN115531272B (zh) | 一种源自高山植物的抗氧化组合物及其制备方法与应用 | |
CN113350234A (zh) | 一种舒敏修复复合物的制备方法与应用 | |
CN109498523B (zh) | 一种防皲裂护肤品及其制备 | |
CN110859785A (zh) | 一种抗敏复合物的制备方法与应用 | |
CN105148288A (zh) | 一种环糊精以及改性环糊精辅助提取中药有效成分的方法 | |
CN116421531B (zh) | 一种保湿抗敏护肤霜及其制备方法 | |
CN111686047A (zh) | 一种具有协同修复效果的修复护肤精华 | |
CN116617106A (zh) | 一种原人参三醇皂苷舒敏修护组合物及其制备方法和应用 | |
CN108785429B (zh) | 一种具有舒缓修复功效的外用中药组合物及其制备方法 | |
CN115300437B (zh) | 一种保湿抗衰护肤组合物及其制备方法和应用 | |
JPH0138762B2 (zh) | ||
CN114886834B (zh) | 美白精华液及其制备方法 | |
CN110755322A (zh) | 金丹抗敏中药提取物及其制备方法与应用 | |
CN110051591A (zh) | 一种含有金莲花纯露的喷雾剂及其制备和应用 | |
CN104983642A (zh) | 具有护肤功效的外用中药组合物、护肤制剂及其制备方法 | |
CN108938929A (zh) | 一种兼具保湿和抗衰老作用的中药组合物及其制备方法和应用 | |
CN102631609B (zh) | 具有皮肤应急修复功效的外用中药组合物、制剂及其制备方法 | |
CN103800559A (zh) | 具有舒缓美白功效的外用中药组合物、制剂及其制备方法 | |
CN108379135B (zh) | 一种紫芝提取物的组合物及其提取工艺和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |